Indaptus Therapeutics (INDP) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Indaptus Therapeutics (INDP) over the past year, losing 22.4% versus a loss of 45.9%. Over five years, RCKT leads with a -90.6% price change compared with -99.0% for INDP. Indaptus Therapeutics is the larger company by market cap ($334.4 million vs $281.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDP | RCKT |
|---|---|---|
| Share price | $2.51 | $2.56 |
| Market cap | $334.44M | $281.02M |
| 1-day change | +5.91% | -2.66% |
| YTD return | -18.56% | -25.07% |
| 1-year return | -45.89% | -22.42% |
| 5-year return | -98.97% | -90.58% |
| EPS (TTM) | $-6.15 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.96 | $5.45 |
| 52-week low | $0.92 | $2.42 |
| Distance from 52-week high | -57.89% | -53.03% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +232.03% |
| Average volume | 836.21K | 1.67M |
| Shares outstanding | 133.24M | 109.77M |
| Employees | 5 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCKT has outperformed INDP by 23.5 percentage points over the past year.
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
INDP vs RCKT FAQ
Which is bigger, Indaptus Therapeutics or Rocket Pharmaceuticals?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $334.44M compared with $281.02M for Rocket Pharmaceuticals (RCKT).
Which stock has performed better over the past year, INDP or RCKT?
RCKT returned -22.42% over the past 12 months, compared with -45.89% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are Indaptus Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.